Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Acquisitions & Divestments (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $60.0 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 7.69% year-over-year to $60.0 million; the TTM value through Dec 2025 reached $246.0 million, down 28.49%, while the annual FY2025 figure was $246.0 million, 28.49% down from the prior year.
  • Change in Acquisitions & Divestments reached $60.0 million in Q4 2025 per AMLX's latest filing, down from $64.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $147.9 million in Q4 2023 and bottomed at $24.9 million in Q1 2022.
  • Average Change in Acquisitions & Divestments over 4 years is $72.7 million, with a median of $64.5 million recorded in 2024.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 335.06% in 2023, then plummeted 56.06% in 2024.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $34.0 million in 2022, then surged by 335.06% to $147.9 million in 2023, then tumbled by 56.06% to $65.0 million in 2024, then dropped by 7.69% to $60.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $60.0 million in Q4 2025, $64.0 million in Q3 2025, and $62.0 million in Q2 2025.